1
|
Caldwell MT, Goyal N, Dudley A, Dehlendorf C, Scott J, Parke D, Vallee P, Daniels G, Manteuffel J, Thomas CSD, Hambrick N, Guetterman TC, Misra D, Joseph CLM. POSTER ABSTRACTS. Contraception 2021. [DOI: 10.1016/j.contraception.2021.07.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Haydon A, Alamgeer M, Brungs D, Collichio F, Khushalani N, Colevas A, Rischin D, Kudchadkar R, Chai-Ho W, Daniels G, Lutzky J, Lee J, Bowyer S, Migden M, Sheladia P, Bommareddy P, He S, Andreu-Vieyra C, Fury M, Hill A. 1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
3
|
Sacco A, Chen R, Ghosh D, Worden F, Wong D, Adkins D, Swiecicki P, Chai-Ho W, Pittman E, Messer K, Gold K, Daniels G, Sutton B, Natsuhara A, Cohen E. An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.376] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Daniels G, Akram S, Westgate GE, Tamburic S. Can plant-derived phytochemicals provide symptom relief for hair loss? A critical review. Int J Cosmet Sci 2019; 41:332-345. [DOI: 10.1111/ics.12554] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 05/23/2019] [Accepted: 06/22/2019] [Indexed: 12/16/2022]
Affiliation(s)
- G. Daniels
- Cosmetic Science Research Group; University of the Arts, London; 20 John Princes Street London U.K
| | - S. Akram
- Cosmetic Science Research Group; University of the Arts, London; 20 John Princes Street London U.K
| | - G. E. Westgate
- Gill Westgate Consultancy Ltd; Stevington Bedfordshire U.K
| | - S. Tamburic
- Cosmetic Science Research Group; University of the Arts, London; 20 John Princes Street London U.K
| |
Collapse
|
5
|
Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM SM registry. J Immunother Cancer 2019; 7:84. [PMID: 30917871 PMCID: PMC6437874 DOI: 10.1186/s40425-019-0567-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 03/14/2019] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess outcomes in patients receiving T-cell checkpoint inhibitory immunotherapy and tyrosine kinase inhibitor therapy, but have not been applied extensively to patients receiving high dose interleukin-2 (HD IL-2) immunotherapy. METHODS Survival of 810 mRCC patients treated from 2006 to 2017 with high dose IL-2 (aldesleukin) and enrolled in the PROCLAIMSM registry data base was assessed utilizing the International Metastatic RCC Database Consortium (IMDC) risk criteria. Median follow-up is 23.4 months (mo.) (range 0.2-124 mo.). Subgroup evaluations were performed by separating patients by prior or no prior therapy, IL-2 alone, or therapy subsequent to IL-2. Some patients were in two groups. We will focus on the 356 patients who received IL-2 alone, and evaluate outcome by risk factor categories. RESULTS Among the 810 patients, 721 were treatment-naïve (89%) and 59% were intermediate risk. Overall, of the 249 patients with favorable risk, the median overall survival (OS) is 63.3 mo. and the 2-year OS is 77.6%. Of 480 patients with intermediate risk, median OS is 42.4 mo., 2-year OS 68.2%, and of 81 patients with poor risk, median OS 14 mo., 2-year OS 40.4%. Among those who received IL-2 alone (356 patients), median OS is 64.5, 57.6, and 14 months for favorable, intermediate and poor risk categories respectively. Two year survival among those treated only with HD IL-2 is 73.4, 63.7 and 39.8%, for favorable, intermediate and poor risk categories respectively. CONCLUSIONS Among mRCC patients treated with HD IL-2, all risk groups have median and 2-year survival consistent with recent reports of checkpoint or targeted therapies for mRCC. Favorable and intermediate risk (by IMDC) patients treated with HD IL-2 have longer OS compared with poor risk patients, with most durable OS observed in favorable risk patients. Favorable risk patients treated with HD IL-2 alone have a 2-year OS of 74%. These data continue to support a recommendation for HD IL-2 for patients with mRCC who meet eligibility criteria. TRIAL REGISTRATION PROCLAIM, NCT01415167 was registered with ClinicalTrials.gov on August 11, 2011, and initiated for retrospective data collection until 2006, and prospective data collection ongoing since 2011.
Collapse
Affiliation(s)
| | | | - J. I. Clark
- Loyola University Medical Center, Maywood, IL USA
| | - A. Alva
- University of Michigan, Ann Arbor, MI USA
| | | | - B. Curti
- Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR USA
| | - Neeraj Agarwal
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT USA
| | - R. Hauke
- Nebraska Cancer Specialist, Omaha, NE USA
| | - K. M. Mahoney
- Beth Israel Deaconess Medical Center, Boston, MA USA
| | - H. Moon
- Southern California Permanente Medical Group, Pasadena, CA USA
| | - J. Treisman
- Medical College of Wisconsin, Milwaukee, WI USA
| | - S. S. Tykodi
- University of Washington and Fred Hutchinson Cancer Center, Seattle, WA USA
| | - G. Daniels
- University of California San Diego, San Diego, CA USA
| | | | | | - H. Kaufman
- Massachusetts General Hospital, Boston, MA USA
| | - N. Gregory
- Prometheus Laboratories, San Diego, CA USA
| | | |
Collapse
|
6
|
Long G, Milhem M, Amin A, Hoimes C, Medina T, Conry R, Lao C, Daniels G, Reddy S, Mehmi I, Andtbacka R, Barve M, Shaheen M, Tueting T, Chisamore M, Xing B, Candia A, Gamelin E, Janssen R, Ribas A. Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.055] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Ribas A, Mehmi I, Medina T, Lao C, Kummar S, Amin A, Deva S, Salama A, Tueting T, Milhem M, Hoimes C, Daniels G, Shaheen M, Jang S, Barve M, Powell A, Chandra S, Schmidt E, Janssen R, Long G. Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
New S, Daniels G, Gummer CL. Measuring the frequency of consumer hair combing and magnitude of combing forces on individual hairs in a tress and the implications for product evaluation and claims substantiation. Int J Cosmet Sci 2018; 40:461-466. [PMID: 30076777 DOI: 10.1111/ics.12485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Accepted: 08/01/2018] [Indexed: 11/28/2022]
Abstract
OBJECTIVES It is commonly assumed that, due to the long growth cycle of hair, multi-cycle combing, and strength and fatigue testing using thousands of cycles is relevant for product evaluation and claim substantiation. The objective was to assess the frequency and magnitude of combing forces on individual hairs against a hypothesis that fibres on a consumer's head rarely experience significant loads during routine combing. METHODS Single fibres were removed from a tress, attached to a load cell and replaced in the tress. Combing of tresses, guided by in-vivo measurements, measured the frequency of significant loads defined as 'events' ≥1 g over 30 combing sets (set = 10 comb strokes @~25 cm s-1 ) with intermediate tangling. Asian and Caucasian hair was assessed by dry, wet, bleached-wet and bleached-dry combing. A questionnaire of 231 Asian and Caucasian women established daily frequency and number of comb strokes for the whole head. In-vivo combing videos of 10 women (five Asian, five Caucasian) were used to establish in-vivo and tress combing speeds. RESULTS The questionnaires returned an average combing frequency of 1.7×/day (range 0-5) and average number of strokes 16 ± 2.3 per head/day (95% CI). Video analysis measured combing speeds of 22-35 cm s-1 across hair types. Tress data confirmed individual fibres are unlikely to experience repeated loading or significant loads in all but wet combed persulphate bleached hair. 'Events' of ≥1 g - dry combing gave an event probability of 0.2 and average load of 1.7 g over 30 comb sets. Dry combed bleached samples returned a probability of 0.23 and 0.3 respectively. Wet combed virgin Asian and Caucasian hair gave a probability of 0.1 and 0.47 respectively. Wet combed bleached hair gave a probability of one. The addition of a conditioner to bleached hair reduced the event probability to <0.1. CONCLUSION During combing, individual fibres may not experience any significant loads and are unlikely to experience repetitive loads >10 g. The low number of comb strokes and low event probability is in keeping with consumers growing their hair long and in good condition. The data indicates the need for a significant rethink of methods used for product evaluation and claim substantiation.
Collapse
Affiliation(s)
- S New
- Fashion Business School London College of Fashion, London, W1B0BJ, U.K
| | - G Daniels
- Fashion Business School London College of Fashion, London, W1B0BJ, U.K
| | - C L Gummer
- Cider Solutions Ltd. Chilworth, Surrey, GU48RR, U.K
| |
Collapse
|
9
|
Daniels G, Finning K, Lozano M, Hyland CA, Liew YW, Powley T, Castilho L, Bonet Bub C, Kutner JM, Banch Clausen F, Christiansen M, Sulin K, Haimila K, Legler TJ, Lambert M, Ryan H, Ní Loingsigh S, Matteocci A, Pierelli L, Dovc Drnovsek T, Bricl I, Nogués N, Muñiz-Diaz E, Olsson ML, Wikman A, de Haas M, van der Schoot CE, Massey E, Westhoff CM. Vox Sanguinis International Forum on application of fetal blood grouping: summary. Vox Sang 2017; 113:198-201. [DOI: 10.1111/vox.12616] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
| | - K. Finning
- International Blood Group Reference Lab; NHS Blood and Transplant; Northway, Filton Bristol BS34 7QH UK
| | - M. Lozano
- Department of Hemotherapy and Hemostasis; University Clinic Hospital; University of Barcelona; Barcelona Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Daniels G, Finning K, Lozano M, Hyland CA, Liew YW, Powley T, Castilho L, Bonet Bub C, Kutner JM, Banch Clausen F, Christiansen M, Sulin K, Haimila K, Legler TJ, Lambert M, Ryan H, Ní Loingsigh S, Matteocci A, Pierelli L, Dovc Drnovsek T, Bricl I, Nogués N, Muñiz-Diaz E, Olsson ML, Wikman A, de Haas M, van der Schoot CE, Massey E, Westhoff CM. Vox Sanguinis International Forum on application of fetal blood grouping. Vox Sang 2017; 113:e26-e35. [DOI: 10.1111/vox.12615] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | | | | | - C. A. Hyland
- Australian Red Cross Blood Service, Research and Development; 44 Musk Avenue, Kelvin Grove Brisbane Qld 4059 Australia
| | - Y.-W. Liew
- Australian Red Cross Blood Service, Research and Development; 44 Musk Avenue, Kelvin Grove Brisbane Qld 4059 Australia
| | - T. Powley
- Australian Red Cross Blood Service, Research and Development; 44 Musk Avenue, Kelvin Grove Brisbane Qld 4059 Australia
| | - L. Castilho
- Departamento de Hemoterapia; Hospital Israelita Albert Einstein; Avenida Albert Einstein, 627-3° andar Bloco E CEP: 05651-901 São Paulo SP Brazil
| | - C. Bonet Bub
- Departamento de Hemoterapia; Hospital Israelita Albert Einstein; Avenida Albert Einstein, 627-3° andar Bloco E CEP: 05651-901 São Paulo SP Brazil
| | - J. M. Kutner
- Departamento de Hemoterapia; Hospital Israelita Albert Einstein; Avenida Albert Einstein, 627-3° andar Bloco E CEP: 05651-901 São Paulo SP Brazil
| | - F. Banch Clausen
- Laboratory of Blood Genetics, Rigshospitalet, Section 2034, Department of Clinical Immunology; Copenhagen University Hospital; Blegdamsvej 9 Copenhagen Denmark
| | - M. Christiansen
- Department of Clinical Immunology; Aarhus University Hospital; Palle Juul-Jensens Boulevard 99 8200 Aarhus N Denmark
| | - K. Sulin
- Blood Group Unit; Finnish Red Cross Blood Service; Kivihaantie 7 FI-00310 Helsinki Finland
| | - K. Haimila
- Blood Group Unit; Finnish Red Cross Blood Service; Kivihaantie 7 FI-00310 Helsinki Finland
| | - T. J. Legler
- Department of Transfusion Medicine; University Medical Center Göttingen; Georg-August-Universität; Robert-Koch-Str. 40 Göttingen 37075 Germany
| | - M. Lambert
- Irish Blood Transfusion Service; Blood Group Genetics; National Blood Centre; James's Street Dublin 8 Ireland
| | - H. Ryan
- Irish Blood Transfusion Service; Blood Group Genetics; National Blood Centre; James's Street Dublin 8 Ireland
| | - S. Ní Loingsigh
- Irish Blood Transfusion Service; Blood Group Genetics; National Blood Centre; James's Street Dublin 8 Ireland
| | - A. Matteocci
- Department of Transfusion Medicine; San Camillo Forlanini Hospital; Circonvallazione Gianicolense 87 00152 Roma Italy
| | - L. Pierelli
- Department of Experimental Medicine; Sapienza University of Rome; Piazzale Aldo Moro 5 00185 Roma Italy
- Department of Transfusion Medicine; San Camillo Forlanini Hospital; Circonvallazione Gianicolense 87 00152 Roma Italy
| | - T. Dovc Drnovsek
- Department of Immunohematology; Blood Transfusion Centre of Slovenia; Slajmerjeva 6 SI-Ljubljana Slovenia
| | - I. Bricl
- Department of Immunohematology; Blood Transfusion Centre of Slovenia; Slajmerjeva 6 SI-Ljubljana Slovenia
| | - N. Nogués
- Immunohematology Department; Banc de Sang i Teixits; Passeig de Taulat 116 08005 Barcelona Spain
| | - E. Muñiz-Diaz
- Immunohematology Department; Banc de Sang i Teixits; Passeig de Taulat 116 08005 Barcelona Spain
| | - M. L. Olsson
- Department of Laboratory Medicine; Lund University; Lund Sweden
- Department of Clinical Immunology and Transfusion Medicine; LabMedicine; Office of Medical Services; Region Skåne Lund Sweden
| | - A. Wikman
- Department of Clinical Immunology and Transfusion Medicine; Karolinska University Hospital and Karolinska Institutet; Stockholm Sweden
| | - M. de Haas
- Sanquin Diagnostic Services; Department of Immunohematology Diagnostics; Sanquin Research; Plesmanlaan 125 1066 CX Amsterdam The Netherlands
- Center for Clinical Transfusion Research; Leiden The Netherlands
- Department of Immunohematology and Blood Transfusion; Leiden University Medical Center; Leiden The Netherlands
| | - C. E. van der Schoot
- Sanquin Research; Plesmanlaan 125 1066 CX Amsterdam The Netherlands
- Department of Experimental Immunohematology; Sanquin Research; Amsterdam The Netherlands
- Landsteiner Laboratory; Academic Medical Centre; University of Amsterdam; Amsterdam The Netherlands
| | - E. Massey
- Diagnostic and Therapeutic Services; NHS Blood and Transplant; North Bristol Park, Northway Filton Bristol BS34 7QH UK
| | - C. M. Westhoff
- Immunohematology and Genomics; New York Blood Center; 310 E 67th St New York NY 10065 USA
| |
Collapse
|
11
|
Boussemart L, Wang A, Wong M, Ross J, Stephens P, Ali S, Sosman J, Mehnert J, Daniels G, Kendra K, Schrock A, Miller V. Hybrid-capture based genomic profiling identifies BRAF V600 and non-V600 alterations in melanoma samples negative by prior testing. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Sznol M, Ferrucci P, Hogg D, Atkins M, Wolter P, Guidoboni M, Lebbe C, Kirkwood J, Schachter J, Daniels G, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Jiang J, Hodi F, Wolchok J. Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Storry JR, Castilho L, Chen Q, Daniels G, Denomme G, Flegel WA, Gassner C, de Haas M, Hyland C, Keller M, Lomas-Francis C, Moulds JM, Nogues N, Olsson ML, Peyrard T, van der Schoot CE, Tani Y, Thornton N, Wagner F, Wendel S, Westhoff C, Yahalom V. International society of blood transfusion working party on red cell immunogenetics and terminology: report of the Seoul and London meetings. ACTA ACUST UNITED AC 2016; 11:118-122. [PMID: 29093749 DOI: 10.1111/voxs.12280] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The Working Party has met twice since the last report: in Seoul, South Korea 2014, and in London, UK 2015, both in association with the International Society of Blood Transfusion (ISBT) Congress. As in previous meetings, matters pertaining to blood group antigen nomenclature were discussed. Eleven new blood group antigens were added to seven blood group systems. This brings the current total of blood group antigens recognized by the ISBT to 346, of which 308 are clustered within 36 blood groups systems. The remaining 38 antigens are currently unassigned to a known blood group system.
Collapse
Affiliation(s)
- J R Storry
- Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden
| | - L Castilho
- University of Campinas/Hemocentro, Campinas, Brazil
| | - Q Chen
- Jiangsu Province Blood Center, Nanjing, China
| | - G Daniels
- Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol, UK
| | - G Denomme
- Blood Center of Wisconsin, Milwaukee, WI, USA
| | - W A Flegel
- Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, USA
| | - C Gassner
- Blutspende Zurich, Zurich, Switzerland
| | - M de Haas
- Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
| | - C Hyland
- Australian Red Cross Blood Services, Brisbane, Qld, Australia
| | - M Keller
- American Red Cross Blood Services, Philadelphia, PA, USA
| | | | | | - N Nogues
- Banc de Sang i Teixits, Barcelona, Spain
| | - M L Olsson
- Department of Laboratory Medicine, Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden
| | - T Peyrard
- Institut National de la Transfusion Sanguine, Département Centre National de Référence pour les Groupes Sanguins, Inserm UMR_S1134, Paris, France
| | | | - Y Tani
- Osaka Red Cross Blood Center, Osaka, Japan
| | - N Thornton
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK
| | - F Wagner
- Red Cross Blood Service NSTOB, Springe, Germany
| | - S Wendel
- Blood Bank, Hospital Sirio-Libanes, São Paulo, Brazil
| | - C Westhoff
- New York Blood Center, New York, NY, USA
| | - V Yahalom
- NBGRL Magen David Adom, Ramat Gan, Israel
| |
Collapse
|
14
|
White J, Qureshi H, Massey E, Needs M, Byrne G, Daniels G, Allard S. Guideline for blood grouping and red cell antibody testing in pregnancy. Transfus Med 2016; 26:246-63. [DOI: 10.1111/tme.12299] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Revised: 02/26/2016] [Accepted: 03/01/2016] [Indexed: 10/22/2022]
Affiliation(s)
- J White
- UK National External Quality Assessment Scheme for Blood Transfusion Laboratory Practice; Watford
| | - H Qureshi
- Department of Haematology; University Hospitals of Leicester
| | - E Massey
- NHS Blood and Transplant & University Hospitals Bristol NHS Foundation Trust
| | - M Needs
- Institute of Biomedical Scientists and NHS Blood and Transplant
| | - G Byrne
- Department of Haematology; University Hospitals of Leicester
| | - G Daniels
- International Blood Group Reference Laboratory; NHS Blood and Transplant
| | - S Allard
- Barts Health NHS Trust and NHS Blood and Transplant
| | | |
Collapse
|
15
|
Zitting K, Horrey W, Liang Y, Daniels G, Shreeve M, Ronda J, Riedner B, Tononi G, Czeisler C, Duffy J. Increased subjective sleepiness and global EEG theta power during a post-night shift drive. Sleep Med 2015. [DOI: 10.1016/j.sleep.2015.02.1378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle 2015; 14:2121-8. [PMID: 25950492 PMCID: PMC4614941 DOI: 10.1080/15384101.2015.1041691] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Fibroblast growth factor ligands and receptors (FGF and FGFR) play critical roles in tumorigenesis, and several drugs have been developed to target them. We report the biologic correlates of FGF/FGFR abnormalities in diverse malignancies. The medical records of patients with cancers that underwent targeted next generation sequencing (182 or 236 cancer-related genes) were reviewed. The following FGF/FGFR genes were tested: FGF3, 4, 6, 7, 10, 12, 14, 19, 23 and FGFR1, 2, 3, and 4. Of 391 patients, 56 (14.3%) had aberrant FGF (N = 38, all amplifications) and/or FGFR (N = 22 including 5 mutations and one FGFR3-TACC3 fusion). FGF/FGFR aberrations were most frequent in breast cancers (26/81, 32.1%, p = 0.0003). In multivariate analysis, FGF/FGFR abnormalities were independently associated with CCND1/2, RICTOR, ZNF703, RPTOR, AKT2, and CDK8 alterations (all P < 0.02), as well as with an increased median number of alterations (P < 0.0001). FGF3, FGF4, FGF19 and CCND1 were co-amplified in 22 of 391 patients (5.6%, P < 0.0001), most likely because they co-localize on the same chromosomal region (11q13). There was no significant difference in time to metastasis or overall survival when comparing patients harboring FGF/FGFR alterations versus those not. Overall, FGF/FGFR was one of the most frequently aberrant pathways in our population comprising patients with diverse malignancies. These aberrations frequently co-exist with anomalies in a variety of other genes, suggesting that tailored combination therapy may be necessary in these patients.
Collapse
Affiliation(s)
- A Parish
- a Center for Personalized Cancer Therapy; University of California San Diego; Moores Cancer Center ; San Diego , CA , USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Soothill PW, Finning K, Latham T, Wreford-Bush T, Ford J, Daniels G. Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHS. BJOG 2014; 122:1682-6. [DOI: 10.1111/1471-0528.13055] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/09/2014] [Indexed: 12/01/2022]
Affiliation(s)
- PW Soothill
- Fetal Medicine Unit; St Michaels Hospital; University Hospitals Bristol NHS Foundation Trust; Bristol UK
| | - K Finning
- NHS Blood and Transplant; International Blood Group Reference Laboratory; Filton Bristol UK
| | - T Latham
- NHS Blood and Transplant; International Blood Group Reference Laboratory; Filton Bristol UK
| | - T Wreford-Bush
- Haematology; Southmead Hospital; Westbury-on-Trym Bristol UK
| | - J Ford
- Fetal Medicine Unit; St Michaels Hospital; University Hospitals Bristol NHS Foundation Trust; Bristol UK
| | - G Daniels
- NHS Blood and Transplant; International Blood Group Reference Laboratory; Filton Bristol UK
| |
Collapse
|
18
|
Storry JR, Castilho L, Daniels G, Flegel WA, Garratty G, de Haas M, Hyland C, Lomas-Francis C, Moulds JM, Nogues N, Olsson ML, Poole J, Reid ME, Rouger P, van der Schoot E, Scott M, Tani Y, Yu LC, Wendel S, Westhoff C, Yahalom V, Zelinski T. International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Cancun report (2012). Vox Sang 2014; 107:90-6. [PMID: 24372289 PMCID: PMC5661873 DOI: 10.1111/vox.12127] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Accepted: 11/14/2013] [Indexed: 12/22/2022]
Abstract
The International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology convened during the International congress in Cancun, July 2012. This report details the newly identified antigens in existing blood group systems and presents three new blood group systems.
Collapse
Affiliation(s)
- J R Storry
- Clinical Immunology and Transfusion Medicine, University and Regional Laboratories, Lund, Sweden
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Karamatic Crew V, Poole J, Burton N, Daniels G. Three uncommonKELalleles in one family with unusual Kell phenotypes explain a 35-year old conundrum. Vox Sang 2013; 106:242-7. [DOI: 10.1111/vox.12094] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
20
|
Saenz R, Messmer B, Futalan D, Tor Y, Larsson M, Daniels G, Esener S, Messmer D. Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization. Mol Immunol 2013; 57:191-9. [PMID: 24172222 DOI: 10.1016/j.molimm.2013.09.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2013] [Revised: 09/19/2013] [Accepted: 09/28/2013] [Indexed: 11/29/2022]
Abstract
We have previously shown that an 18 amino acid long peptide, named Hp91, whose sequence corresponds to a region within the endogenous protein HMGB1, activates dendritic cells (DCs) and acts as adjuvant in vivo by potentiating Th1-type antigen-specific immune responses. We analyzed the structure-function relationship of the Hp91 peptide to investigate the amino acids and structure responsible for immune responses. We found that the cysteine at position 16 of Hp91 enabled formation of reversible peptide dimmers, monomer and dimmer were compared for DC binding and activation. Stable monomers and dimers were generated using a maleimide conjugation reaction. The dimer showed enhanced ability to bind to and activate DCs. Furthermore, the C-terminal 9 amino acids of Hp91, named UC1018 were sufficient for DC binding and Circular dichroism showed that UC1018 assumes an alpha-helical structure. The ninemer peptide UC1018 induced more potent antigen-specific CTL responses in vivo as compared to Hp91 and it protected mice from tumor development when used in a prophylactic vaccine setting. We have identified a short alpha helical peptide that acts as potent adjuvant inducing protective immune responses in vivo.
Collapse
Affiliation(s)
- R Saenz
- Rebecca and John Moores Cancer Center, University of California San Diego (UCSD), La Jolla, CA 92093, USA
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Searle CJ, Smith K, Daniels G, Maher EJ, Quarrell O. Cell-free fetal DNA sex determination identified a maternal SRY gene with a known X chromosome deletion. Prenat Diagn 2013; 33:612-3. [PMID: 23553470 DOI: 10.1002/pd.4078] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C J Searle
- Department of Clinical Genetics, Sheffield Children's NHS Foundation Trust, Sheffield, S10 2TH, UK.
| | | | | | | | | |
Collapse
|
22
|
Taulbut M, Walsh D, Parcell S, Hartmann A, Poirier G, Strniskova D, Daniels G, Hanlon P. What can ecological data tell us about reasons for divergence in health status between West Central Scotland and other regions of post-industrial Europe? Public Health 2013; 127:153-63. [DOI: 10.1016/j.puhe.2012.11.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Revised: 08/29/2012] [Accepted: 11/10/2012] [Indexed: 11/28/2022]
|
23
|
Boyle J, Thorpe SJ, Hawkins JR, Lockie C, Fox B, Matejtschuk P, Halls C, Metcalfe P, Rigsby P, Armstrong-Fisher S, Varzi AM, Urbaniak S, Daniels G. International reference reagents to standardise blood group genotyping: evaluation of candidate preparations in an international collaborative study. Vox Sang 2012; 104:144-52. [DOI: 10.1111/j.1423-0410.2012.01641.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
24
|
Tamburic S, Grant-Ross P, Labedzka M, Daniels G. Exploring the effects of non-medical versus medical approaches to the management of skin aging in women over sixty. Int J Cosmet Sci 2012; 34:481-8. [PMID: 22809000 DOI: 10.1111/j.1468-2494.2012.00741.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Accepted: 07/10/2012] [Indexed: 11/28/2022]
Abstract
This study was a pilot project, set up to assess ageing skin using a multi-disciplinary approach. The main aim of this study was to evaluate whether the use of more radical ('medical') treatments in the management of skin ageing would bring superior results and ultimately make people look younger, than the use of cosmetics ('non-medical' treatments). A simple post-hoc study design was used, whereby medical treatments varied within the group, all of them completed at least 2 weeks before the start of the study. In addition, it was of interest to assess the suitability of the proposed combination of methods. A total of 21 female participants were recruited for this study: 11 for the non-medical and 10 for the medical group. The multi-disciplinary approach consisted of instrumental measurements, self-assessment, expert assessment by Merz scales and a public perception survey. The majority of nearly 70 sets of instrumental skin data obtained in this study did not differ significantly between the non-medical and the medical group. However, the medical group gave higher self-assessment scores for their faces. The scores for hands were lower than scores for faces by both groups. This was partly supported by instrumental data (lower skin hydration on hands than on the face). The findings of the public perception survey of nine matched pairs of subjects scored the non-medical group as younger looking. Data analysis has shown that the judgement of youthfulness did not depend on either the gender or the age of observers.
Collapse
Affiliation(s)
- S Tamburic
- School of Management and Science, London College of Fashion, University of the Arts London, 20 John Prince's Street, London, W1G OBJ, U.K.
| | | | | | | |
Collapse
|
25
|
|
26
|
Storry JR, Castilho L, Daniels G, Flegel WA, Garratty G, Francis CL, Moulds JM, Moulds JJ, Olsson ML, Poole J, Reid ME, Rouger P, van der Schoot E, Scott M, Smart E, Tani Y, Yu LC, Wendel S, Westhoff C, Yahalom V, Zelinski T. International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Berlin report. Vox Sang 2011; 101:77-82. [PMID: 21401621 DOI: 10.1111/j.1423-0410.2010.01462.x] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- J R Storry
- Clinical Immunology and Transfusion Medicine, University and Regional Laboratories, Lund, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
|
28
|
Hill M, Finning K, Martin P, Hogg J, Meaney C, Norbury G, Daniels G, Chitty LS. Non-invasive prenatal determination of fetal sex: translating research into clinical practice. Clin Genet 2010; 80:68-75. [DOI: 10.1111/j.1399-0004.2010.01533.x] [Citation(s) in RCA: 127] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
29
|
Satchwell T, van den Akker E, Daniels G, Toye A. Investigating band 3 multiprotein complex assembly during erythropoiesis. Transfus Clin Biol 2010. [DOI: 10.1016/j.tracli.2010.06.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Pellegrin S, van den Akker E, Satchwell T, Green C, Daniels G, Toye A. Apoptosis of primary human erythroid progenitors induced by erythropoietin withdrawal. Transfus Clin Biol 2010. [DOI: 10.1016/j.tracli.2010.06.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
|
32
|
Tilley L, Green C, Poole J, Gaskell A, Ridgwell K, Burton NM, Uchikawa M, Tsuneyama H, Ogasawara K, Akkøk CA, Daniels G. A new blood group system, RHAG: three antigens resulting from amino acid substitutions in the Rh-associated glycoprotein. Vox Sang 2009; 98:151-9. [PMID: 19744193 DOI: 10.1111/j.1423-0410.2009.01243.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND OBJECTIVES Rh-associated glycoprotein (RhAG) is closely associated with the Rh proteins in the red cell membrane. Two high frequency antigens (Duclos and DSLK) and one low frequency antigen (Ol(a)) have serological characteristics suggestive of expression on RhAG. MATERIALS AND METHODS RHAG was sequenced from the DNA of one Duclos-negative, one DSLK-negative, and two Ol(a+) individuals. Recombinant protein was expressed in HEK 293 cells. Protein models with RhAG subunits were constructed. RESULTS The original Duclos-negative patient was homozygous for RHAG 316C>G, encoding Gln106Glu. HEK 293 cells expressing Gln106Glu mutant RhAG did not react with anti-Duclos. An individual with DSLK-negative red cells was homozygous for 490A>C, encoding Lys164Gln. Two Ol(a+) members of the original Norwegian family were heterozygous for 680C>T, encoding Ser227Leu. A Japanese donor with Rh(mod) phenotype had Ol(a+) red cells and was homozygous for 680C>T. CONCLUSION The three red cell antigens encoded by RHAG form the RHAG blood group system: Duclos is RHAG1 (030001); Ol(a) is RHAG2 (030002); and DSLK is provisionally RHAG3 (030003).
Collapse
Affiliation(s)
- L Tilley
- International Blood Group Reference Laboratory and Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Senzer NN, Kaufman H, Amatruda T, Nemunaitis M, Daniels G, Glaspy J, Goldsweig H, Coffin RS, Nemunaitis J. Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9035] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9035 Background: OncoVEXGM-CSF is a an oncolytic HSV, encoding GM-CSF . We recently completed a phase II trial involving 50 advanced melanoma patients (stage IIIc and IV) with at least one injection accessible lesion, including by ultrasound. Methods: Patients received a single IT injection of 106 pfu/ml apportioned between 10 or less injectable tumors, followed 3 wks later by 24 or less sequential injections of 108 pfu/ml every 2 wks until clinically significant disease progression, or overall or injectable lesion complete response. Response (RECIST modified to allow progression before response and biopsy of residual masses) and survival were monitored. Results: All 50 pts have been enrolled and are evaluable (Stage IIIc, n=10; IV M1a, n=16; IV M1b, n=4; IV M1c, n=20). A median of 6 injections were administered. Adverse effects were limited and generally involved transient flu-like symptoms. Both injected and uninjected regional and distant disease demonstrated response including clearly documented responses at uninjected visceral sites. The overall response rate was 26% (8 CR, 5 PR); 10 responses have been maintained for >6 months and 2 are ongoing at <6months, the longest currently being at 35 months from first dose. 93% of patients (14 of 15) with PR, CR or surgical CR remain alive. Ten additional patients had SD for >3 months. Kaplan Meier one year survival is 61% overall, 58% stage IV only, 48% for Stage IV M1c. The median OS is 16+ months. Conclusions: The 1-year survival and durable objective response rate are encouraging. Responses of distant and visceral disease provide further compelling evidence of systemic effectiveness. This, combined with a limited toxicity profile, suggests OncoVEXGM-CSF is a promising treatment for metastatic melanoma. A phase III clinical trial is planned. [Table: see text]
Collapse
Affiliation(s)
- N. N. Senzer
- MCMRC, Dallas, TX; Columbia University, New York, NY; Hubert H. Humphrey Cancer Center, Minneapolis, MN; UCSD, San Diego, CA; UCLA, Los Angeles, CA; BioVex, Inc., Woburn, MA
| | - H. Kaufman
- MCMRC, Dallas, TX; Columbia University, New York, NY; Hubert H. Humphrey Cancer Center, Minneapolis, MN; UCSD, San Diego, CA; UCLA, Los Angeles, CA; BioVex, Inc., Woburn, MA
| | - T. Amatruda
- MCMRC, Dallas, TX; Columbia University, New York, NY; Hubert H. Humphrey Cancer Center, Minneapolis, MN; UCSD, San Diego, CA; UCLA, Los Angeles, CA; BioVex, Inc., Woburn, MA
| | - M. Nemunaitis
- MCMRC, Dallas, TX; Columbia University, New York, NY; Hubert H. Humphrey Cancer Center, Minneapolis, MN; UCSD, San Diego, CA; UCLA, Los Angeles, CA; BioVex, Inc., Woburn, MA
| | - G. Daniels
- MCMRC, Dallas, TX; Columbia University, New York, NY; Hubert H. Humphrey Cancer Center, Minneapolis, MN; UCSD, San Diego, CA; UCLA, Los Angeles, CA; BioVex, Inc., Woburn, MA
| | - J. Glaspy
- MCMRC, Dallas, TX; Columbia University, New York, NY; Hubert H. Humphrey Cancer Center, Minneapolis, MN; UCSD, San Diego, CA; UCLA, Los Angeles, CA; BioVex, Inc., Woburn, MA
| | - H. Goldsweig
- MCMRC, Dallas, TX; Columbia University, New York, NY; Hubert H. Humphrey Cancer Center, Minneapolis, MN; UCSD, San Diego, CA; UCLA, Los Angeles, CA; BioVex, Inc., Woburn, MA
| | - R. S. Coffin
- MCMRC, Dallas, TX; Columbia University, New York, NY; Hubert H. Humphrey Cancer Center, Minneapolis, MN; UCSD, San Diego, CA; UCLA, Los Angeles, CA; BioVex, Inc., Woburn, MA
| | - J. Nemunaitis
- MCMRC, Dallas, TX; Columbia University, New York, NY; Hubert H. Humphrey Cancer Center, Minneapolis, MN; UCSD, San Diego, CA; UCLA, Los Angeles, CA; BioVex, Inc., Woburn, MA
| |
Collapse
|
34
|
|
35
|
Hustinx H, Poole J, Bugert P, Gowland P, Still F, Fontana S, Scharberg EA, Tilley L, Daniels G, Niederhauser C. Molecular basis of the Rh antigen RH48 (JAL). Vox Sang 2009; 96:234-9. [PMID: 19207167 DOI: 10.1111/j.1423-0410.2008.01142.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- H Hustinx
- Blood Transfusion Service SRC Bern, Murtenstrasse 133, Berne, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Daniels G, Castilho L, Flegel WA, Fletcher A, Garratty G, Levene C, Lomas-Francis C, Moulds JM, Moulds JJ, Olsson ML, Overbeeke M, Poole J, Reid ME, Rouger P, van der Schoot E, Scott M, Sistonen P, Smart E, Storry JR, Tani Y, Yu LC, Wendel S, Westhoff C, Yahalom V, Zelinski T. International Society of Blood Transfusion Committee on terminology for red blood cell surface antigens: Macao report. Vox Sang 2009; 96:153-6. [PMID: 19152607 DOI: 10.1111/j.1423-0410.2008.01133.x] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- G Daniels
- Bristol Institute for Transfusion Sciences and The International Blood Group Reference Laboratory, NHS Blood and Transplant, Filton, Bristol, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
|
38
|
van der Schoot CE, de Haas M, Engelfriet CP, Reesink HW, Panzer S, Jungbauer C, Schwartz DMW, Mayr WR, Castilho L, St-Louis M, Long A, Denomme G, Semple E, Fernandes B, Flegel WA, Wagner F, Doescher A, Poli F, Villa MA, Paccapelo C, Karpasitou K, Veldhuisen B, Nogués N, Muñiz-Diaz E, Daniels G, Martin P, Finning K, Reid ME. Genotyping for red blood cell polymorphisms. Vox Sang 2009; 96:167-79. [DOI: 10.1111/j.1423-0410.2008.01131.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Daniels G. Lutheran. Immunohematology 2009; 25:152-159. [PMID: 20406022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The Lutheran blood group system consists of 19 antigens: four pairs of antithetical antigens--Lu(a)/Lu(b), Lu6/Lu9, Lu8/Lu14, and Au(a)/Au(b)--and 11 antigens of very high frequency. These antigens are located on four of the five immunoglobulin-like domains of both isoforms of the Lutheran glycoprotein. The LU gene is on chromosome 19 and comprises 15 exons. The two glycoprotein isoforms differ in the length of their cytoplasmic tails as a result of alternative splicing of intron 13. Lu(null) phenotype arises from homozygosity for inactivating mutations in the LU gene.The dominantly inherited Lu(mod) phenotype, In(Lu), results from heterozygosity for inactivating mutations in KLF1, the gene for the erythroid transcription binding factor EKLF. Clinically, antibodies of the Lutheran system are relatively benign. When hemolytic, they generally cause only mild, delayed hemolytic transfusion reactions or hemolytic disease of the fetus and newborn that can be treated by phototherapy. The Lutheran glycoproteins, which are members of the immunoglobulin superfamily of adhesion molecules and receptors, bind isoforms of laminin with alpha5 chains,components of the extracellular matrix abundant in vascular endothelia. The primary function of the Lutheran glycoproteins on RBCs could involve the transfer of maturing RBCs from the bone marrow to the peripheral circulation. They could also be involved in vascular occlusion and thrombotic events as complications of sickle cell disease and polycythemia vera, respectively.
Collapse
Affiliation(s)
- G Daniels
- Bristol Institute for Transfusion Sciences, National Health Service, Blood and Transplant, North Bristol Park, Bristol, UK
| |
Collapse
|
40
|
Abstract
A major concern of using viral gene therapy is the potential for uncontrolled vector propagation and infection that might result in serious deleterious effects. To enhance the safety, several viral vectors, including vectors based on Sindbis virus, were engineered to lose their capability to replicate and spread after transduction of target cells. Such designs, however, could dramatically reduce the therapeutic potency of the viral vectors, resulting in the need for multiple dosages to achieve treatment goals. Earlier, we showed that a replication-defective (RD) Sindbis vector achieved specific tumor targeting without any adverse effects in vivo. Here, we present a replication-competent Sindbis viral vector that has an hsvtk suicide gene incorporated into ns3, an indispensable non-structural gene for viral survival. The capability of viral propagation significantly increases tumor-specific infection and enhances growth suppression of tumor compared with the conventional RD vectors. Furthermore, in the presence of the prodrug ganciclovir, the hsvtk suicide gene serves as a safety mechanism to prevent uncontrolled vector propagation. In addition to suppressing vector propagation, toxic metabolites, generated by prodrug activation, could spread to neighboring uninfected tumor cells to further enhance tumor killing.
Collapse
Affiliation(s)
- J-C Tseng
- NYU Cancer Institute and the NYU Gene Therapy Center, Department of Pathology, NYU School of Medicine, New York University, New York, NY 10016, USA
| | | | | |
Collapse
|
41
|
Abstract
The external membrane of the red cell contains numerous proteins that either cross the lipid bilayer one or more times or are anchored to it through a lipid tail. Many of these proteins express blood group activity. The functions of some of these proteins are known; in others their function can only be surmised from the protein structure or from limited experimental evidence. They are loosely divided into four categories based on their functions: membrane transporters; adhesion molecules and receptors; enzymes; and structural proteins that link the membrane with the membrane skeleton. Some of the proteins carry out more than one of these functions. Some proteins may complete their major functions during erythropoiesis or may only be important under adverse physiological conditions. Furthermore, some might be evolutionary relics and may no longer have significant functions. Polymorphisms or rare changes in red cell surface proteins are often responsible for blood groups. The biological significance of these polymorphisms or the selective pressures responsible for their stability within populations are mostly not known, although exploitation of the proteins by pathogenic micro-organisms has probably played a major role.
Collapse
Affiliation(s)
- G Daniels
- Bristol Institute for Transfusion Sciences, National Health Service Blood and Transplant, Bristol, UK.
| |
Collapse
|
42
|
Daniels G, Finning K, Martin P, Summers J. Fetal RhD genotyping: A more efficient use of anti-D immunoglobulin. Transfus Clin Biol 2007; 14:568-71. [DOI: 10.1016/j.tracli.2008.03.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2008] [Accepted: 03/04/2008] [Indexed: 10/22/2022]
|
43
|
Abstract
The second International Society of Blood Transfusion and International Council for Standardization in Haematology workshop on molecular blood group genotyping was held in 2006. Forty-one laboratories participated. Six samples were distributed: two representing DNA from transfusion-dependent patients for testing for all clinically important polymorphisms; two representing DNA from amniotic fluid for RhD, Rhc, and K testing; and two plasma samples from RhD-negative pregnant women for fetal RhD testing (only tested by 20 laboratories). Overall, a high level of accuracy was achieved by most of the laboratories, although the error rate caused by RHDPsi was not acceptable and needs to be addressed. With greater care and attention to detail, very high standards could be set for molecular blood group genotyping.
Collapse
Affiliation(s)
- G Daniels
- International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, UK.
| | | | | |
Collapse
|
44
|
Daniels G, Flegel WA, Fletcher A, Garratty G, Levene C, Lomas-Francis C, Moulds JM, Moulds JJ, Olsson ML, Overbeeke MAM, Poole J, Reid ME, Rouger P, van der Schoot CE, Scott M, Sistonen P, Smart E, Storry JR, Tani Y, Yu LC, Wendel S, Westhoff CM, Zelinski T. International Society of Blood Transfusion Committee on Terminology for Red Cell Surface Antigens: Cape Town report. Vox Sang 2007; 92:250-3. [PMID: 17348875 DOI: 10.1111/j.1423-0410.2007.00887.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- G Daniels
- Bristol Institute for Transfusion Sciences, National Blood Service, Bristol, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Tilley L, Bullock T, Mason R, Poole J, Daniels G. P36 A Novel RhD Variant. Transfus Med 2006. [DOI: 10.1111/j.1365-3148.2006.00694_36.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
|
47
|
|
48
|
Catherwood M, Curran MC, Wylie J, Daniels G, Martin P, Morris K. P37 Molecular and Serologic Characterization of RhD Status. Transfus Med 2006. [DOI: 10.1111/j.1365-3148.2006.00694_37.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
|
50
|
Tilley L, Green C, Daniels G. Sequence variation in the 5' untranslated region of the human A4GALT gene is associated with, but does not define, the P1 blood-group polymorphism. Vox Sang 2006; 90:198-203. [PMID: 16507021 DOI: 10.1111/j.1423-0410.2006.00746.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND OBJECTIVE The gene responsible for the P1 polymorphism of the P blood-group system remains unidentified, although the A4GALT gene, whose product is responsible for the production of P(k), has been implicated. No coding differences in A4GALT account for the P1 polymorphism, but homozygosity for two polymorphisms (-551_-550insC and -160A>G) in the 5' untranslated region of the gene has been reported to be unique to Japanese P1- individuals. This study aimed to confirm this correlation in a larger number of British individuals. MATERIALS AND METHODS Serologically confirmed P1+ (n = 35) and P1- (n = 15) individuals were genotyped for polymorphisms in the 5' untranslated region of A4GALT. RESULTS In addition to those previously reported, a further polymorphism, -164C>T, was identified. All P1- individuals were homozygous for -551_-550insC and -160G as compared with 10 of 35 (29%) P1+ individuals (P = 0.000003, two-tailed Fisher's exact test). Allele frequencies for all polymorphisms and estimated haplotype frequencies across the region differed significantly between P1+ and P1- groups. CONCLUSIONS Homozygosity for the A4GALT-551_-550insC and -160G allele is significantly associated with, but not restricted to, the P1- phenotype. No single A4GALT genotype or haplotype was unique to P1- individuals. Thus, A4GALT cannot be unequivocally confirmed as the gene responsible for the P1 phenotype.
Collapse
Affiliation(s)
- L Tilley
- Bristol Institute for Transfusion Sciences, National Blood Service, Bristol, UK.
| | | | | |
Collapse
|